Tivic Health Systems Inc. (TIVC)
NASDAQ (CM) NASDAQ (CM) Primary 
Tivic Health Systems Inc. (TIVC) Q1 2025 Earnings Call Transcript
Tivic Health Systems Inc. (NASDAQ:TIVC ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Jennifer Ernst – Chief Executive Officer Lisa Wolf – Interim Chief Financial Officer Michael Handley – Chief Operating Officer and President-Tivic Biopharma Division Conference Call Participants Operator Welcome to Tivic Health Systems First Quarter 2025 Financial Results and Operational Update Conference Call. This call has been prerecorded, and the questions you have submitted in advance will be answered following the prepared remarks.
Tivic Expands VNS Intellectual Property Portfolio
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled “Vagus Nerve Stimulation System” expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus.
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™. Neutropenia is a condition characterized b.
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health's common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “TIVC.” About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics com.
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript
Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Officer Operator Welcome to Tivic Health Systems Year-End 2024 Financial Results and Operational Update Conference Call. This call has been prerecorded and the questions you have submitted in advance will be answered following prepared remarks.
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. “The important strategic events of the past several months have been nothing short of transformative,” stated Tivic Health Chief Executive Officer, Jennifer Ernst. “We have successfully reshaped the.
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID.
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to c.
Tivic Health Systems, Inc. Announces Reverse Stock Split
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic Health” or the “Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (“Nasdaq”), and is part of the.
Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled “Method and Apparatus for Electrical Stimulation of the Vagus Nerve,” expands the claims and protection around the technology in advance of potential U.S. Food &.
CEO Letter to Shareholders Issued by Tivic Health
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I'd like to take this opportunity to recap some of the important developments this year and share some of our expectations for 2025. Improvements in Commercial Business: We launched ClearUP 2.0, resulting in improved c.
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. “This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," st.
